Price
CHART BY
Frequently asked questions
What is Neuraxis's market capitalization?
The market capitalization of Neuraxis is $91.80M. Market capitalization is a measure of the total market value of a publicly traded company. It is calculated by multiplying the current stock price by the total number of outstanding shares.
What is the Earnings Per Share (EPS) for Neuraxis?
Neuraxis's Earnings Per Share (EPS) over the trailing twelve months (TTM) is -$0.78. EPS indicates the company's profitability on a per-share basis.
What are the analyst ratings and target price for Neuraxis's stock?
Currently, 1 analysts cover Neuraxis's stock, with a consensus target price of $13.00. Analyst ratings provide insights into the stock's expected performance.
What is Neuraxis's revenue over the trailing twelve months?
Over the trailing twelve months, Neuraxis reported a revenue of $5.32M.
What is the EBITDA for Neuraxis?
Neuraxis's Earnings before interest, taxes, depreciation, and amortization (EBITDA) over the trailing twelve months is -$7.61M. EBITDA measures the company's overall financial performance.
What is the free cash flow of Neuraxis?
Neuraxis has a free cash flow of -$5.63M. Free cash flow indicates the cash generated after accounting for cash outflows to support operations and capital assets.
How many employees does Neuraxis have, and what sector and industry does it belong to?
Neuraxis employs approximately 24 people. It operates in the Health Care sector, specifically within the Medical Specialties industry.
What is the free float of Neuraxis's shares?
The free float of Neuraxis is 8.55M. Free float refers to the number of shares available for public trading, excluding restricted shares.
Financials
- Market Cap
- $91.80M
- EPS (TTM)
- -$0.78
- Free Float
- 8.55M
- Revenue (TTM)
- $5.32M
- EBITDA (TTM)
- -$7.61M
- Free Cashflow (TTM)
- -$5.63M
Pricing
- 52W span
- $2.27$9.28
Analyst Ratings
The price target is $13.00 and the stock is covered by 1 analysts.
Buy
1
Hold
0
Sell
0
Information
NeurAxis, Inc. engages in the provision of neuromodulation therapies to address chronic and debilitating conditions in children. Its product, IB-Stim, is a non-surgical device that works by sending gentle electrical impulses into cranial nerve bundles located in the ear. The company was founded by Gary Peterson and Christopher Robin Brown in 2011 and is headquartered in Carmel, IN.
- Employees
- 24
- Industries
- Medical Specialties
- Sector
- Health Care
Identifier
- Primary Ticker
- NRXS
Fundamentals & EOD data from FactSet